Niacin and Progression of CKD

American Journal of Kidney Diseases

Volumn 65, Issue 5, 2015, Pages 785-798

  Streja, Elani ^a   Kovesdy, Csaba P ^b,c   Streja, Dan A ^d,e   Moradi, Hamid ^a   Kalantar Zadeh, Kamyar ^a   Kashyap, Moti L ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d Infosphere Clinical Research   (United States)

^e Providence Medical Group   (United States)

^f VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

cardiovascular disease; chronic kidney disease; HDL function; hyperphosphatemia; Niacin; phosphorus absorption

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHORUS; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; RENAL PROTECTION; REVIEW; BLOOD; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG EFFECTS; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; VASCULAR ENDOTHELIUM;

COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; HYPOLIPIDEMIC AGENTS; NIACIN; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC; TRIGLYCERIDES;

EID: 84929028625     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.11.033     Document Type: Review

References (175)

1. Centers for Disease Control and Prevention National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2010 2010 US Department of Health and Human Services, CDC Atlanta, GA
2. A.A. Honeycutt, J.E. Segel, X. Zhuo, T.J. Hoerger, K. Imai, and D. Williams Medical costs of CKD in the Medicare population J Am Soc Nephrol 24 2013 1478 1483
3. B.C. Astor, K. Matsushita, R.T. Gansevoort, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts Kidney Int 79 2011 1331 1340
4. National Kidney Foundation KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access Am J Kidney Dis 48 suppl 1 2006 S1 S322
5. F. Ismail-Beigi, T. Craven, M.A. Banerji, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 2010 419 430
6. L. Agrawal, N. Azad, N.V. Emanuele, et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial Diabetes Care 34 2011 2090 2094
7. J.C. Peterson, S. Adler, J.M. Burkart, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 1995 754 762
8. W.C. Cushman, G.W. Evans, R.P. Byington, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
9. C.P. Kovesdy, A.J. Bleyer, M.Z. Molnar, et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study Ann Intern Med 159 2013 233 242
10. T.H. Hostetter Prevention of end-stage renal disease due to type 2 diabetes N Engl J Med 345 2001 910 912
11. D.M. Kent, T.H. Jafar, R.A. Hayward, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease J Am Soc Nephrol 18 2007 1959 1965
12. R.A. Altschul, A. Hoffer, and J.D. Stephen Influence of nicotinic acid on serum cholesterol in man Arch Biochem 54 1955 558
13. V.S. Kamanna, S.H. Ganji, and M.L. Kashyap Niacin: an old drug rejuvenated Curr Atheroscler Rep 11 2009 45 51
14. HPS2-Thrive Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
15. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, T. Anderson, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
16. HPS2-Thrive Collaborative Group M.J. Landray, R. Haynes, J.C. Hopewell, et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
17. V.S. Kamanna, S.H. Ganji, and M.L. Kashyap Recent advances in niacin and lipid metabolism Curr Opin Lipidol 24 2013 239 245
18. I. Reiche, S. Westphal, J. Martens-Lobenhoffer, U. Troger, C. Luley, and S.M. Bode-Boger Pharmacokinetics and dose recommendations of Niaspan(R) in chronic kidney disease and dialysis patients Nephrol Dial Transplant 26 2011 276 282
19. K.H. Cho, H.J. Kim, B. Rodriguez-Iturbe, and N.D. Vaziri Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure Am J Physiol Renal Physiol 297 2009 F106 F113
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
21. C. Iribarren The metabolic syndrome is no better than its components Minerva Cardioangiol 55 2007 487 489
22. M. Kurella, J.C. Lo, and G.M. Chertow Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults J Am Soc Nephrol 16 2005 2134 2140
23. K. Rowley, K. O'Dea, and J.D. Best Association of albuminuria and the metabolic syndrome Curr Diabetes Rep 3 2003 80 86
24. H.T. Kang, J.Y. Shim, Y.J. Lee, et al. Association between the ratio of triglycerides to high-density lipoprotein cholesterol and chronic kidney disease in Korean adults: the 2005 Korean National Health and Nutrition Examination Survey Kidney Blood Press Res 34 2011 173 179
25. S. Moura Rdo, D.F. Vasconcelos, E. Freitas, F.J. de Moura, T.T. Rosa, and J.P. Veiga Cystatin C, CRP, log TG/HDLc and metabolic syndrome are associated with microalbuminuria in hypertension Arq Bras Cardiol 102 2014 54 59
26. K. Tsuruya, H. Yoshida, M. Nagata, et al. Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population Atherosclerosis 233 2014 260 267
27. R. Kawamoto, K. Kohara, Y. Tabara, et al. An association between body mass index and estimated glomerular filtration rate Hypertens Res 31 2008 1559 1564
28. P.H. Lee, H.Y. Chang, C.W. Tung, et al. Hypertriglyceridemia: an independent risk factor of chronic kidney disease in Taiwanese adults Am J Med Sci 338 2009 185 189
29. Y. Li, C. Zhou, X. Shao, et al. Hypertriglyceridemic waist phenotype and chronic kidney disease in a Chinese population aged 40 years and older PLoS One 9 2014 e92322
30. J. Ming, S. Xu, and C. Yang et al. China National D, Metabolic Disorders Study Group. Metabolic syndrome and chronic kidney disease in general Chinese adults: results from the 2007-08 China National Diabetes and Metabolic Disorders Study Clin Chim Acta 430 2014 115 120
31. J.C. Rutledge, K.F. Ng, H.H. Aung, and D.W. Wilson Role of triglyceride-rich lipoproteins in diabetic nephropathy Nat Rev Nephrol 6 2010 361 370
32. H. Moradi, M.V. Pahl, R. Elahimehr, and N.D. Vaziri Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease Transl Res 153 2009 77 85
33. T. Speer, S. Zewinger, and D. Fliser Uraemic dyslipidaemia revisited: role of high-density lipoprotein Nephrol Dial Transplant 28 2013 2456 2463
34. K. Kalantar-Zadeh, J.D. Kopple, N. Kamranpour, A.M. Fogelman, and M. Navab HDL-inflammatory index correlates with poor outcome in hemodialysis patients Kidney Int 72 2007 1149 1156
35. P.J. Barter, M. Caulfield, M. Eriksson, et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
36. G.G. Schwartz, A.G. Olsson, M. Abt, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
37. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
38. C.P. Cannon, H.M. Dansky, and M. Davidson et al. Design of the DEFINE trial: Determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib Am Heart J 158 2009 513 519.e513
39. No authors listed Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 2001 905 910
40. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, G. Steiner DAIS Investigators Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 2005 485 493
41. A. Keech, R.J. Simes, P. Barter, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
42. T.M. Davis, R. Ting, J.D. Best, et al. Fenofibrate I, Event Lowering in Diabetes Study I. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2011 280 290
43. ACCORD Study Group H.N. Ginsberg, M.B. Elam, L.C. Lovato, et al. Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
44. J.C. Mychaleckyj, T. Craven, U. Nayak, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants Diabetes Care 35 2012 1008 1014
45. D.E. Bonds, T.E. Craven, J. Buse, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience Diabetologia 55 2012 1641 1650
46. E.K. Hoogeveen, J.M. Geleijnse, D. Kromhout, et al. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial Clin J Am Soc Nephrol 9 2014 1676 1683
47. J. Wu, Y. Song, H. Li, and J. Chen Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report Eur J Clin Pharmacol 65 2009 1169 1174
48. K.H. Cho, H.J. Kim, V.S. Kamanna, and N.D. Vaziri Niacin improves renal lipid metabolism and slows progression in chronic kidney disease Biochim Biophys Acta 1800 2010 6 15
49. M.S. Yee, D.V. Pavitt, W. Richmond, et al. Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy Atherosclerosis 205 2009 528 532
50. A. Owada, S. Suda, and T. Hata Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial Am J Med 114 2003 347 353
51. T.M. Lee, and N.C. Chang Effect of nicorandil on proteinuria in well controlled hypertensive patients J Hypertens 27 2009 618 625
52. J. Himmelfarb, P. Stenvinkel, T.A. Ikizler, and R.M. Hakim The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 2002 1524 1538
53. M. Jun, V. Venkataraman, M. Razavian, et al. Antioxidants for chronic kidney disease Cochrane Database Syst Rev 10 2012 CD008176
54. N.D. Vaziri Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension Curr Opin Nephrol Hypertens 13 2004 93 99
55. H. Vlassara, M. Torreggiani, J.B. Post, F. Zheng, J. Uribarri, and G.E. Striker Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging Kidney Int Suppl 114 2009 S3 S11
56. H. Ha, I.A. Hwang, J.H. Park, and H.B. Lee Role of reactive oxygen species in the pathogenesis of diabetic nephropathy Diabetes Res Clin Pract 82 suppl 1 2008 S42 S45
57. H. Ha, M.R. Yu, Y.J. Choi, M. Kitamura, and H.B. Lee Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells J Am Soc Nephrol 13 2002 894 902
58. R. Hernandez-Marco, and P. Codoner-Franch Pons Morales S, Del Castillo Villaescusa C, Boix Garcia L, Valls Belles V. Oxidant/antioxidant status and hyperfiltration in young patients with type 1 diabetes mellitus Pediatr Nephrol 24 2009 121 127
59. H.F. Tbahriti, A. Kaddous, M. Bouchenak, and K. Mekki Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients Biochem Res Int 2013 2013 358985
60. B. Descamps-Latscha, V. Witko-Sarsat, T. Nguyen-Khoa, et al. Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers Kidney Int 66 2004 1606 1612
61. R. Camilla, H. Suzuki, V. Dapra, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy Clin J Am Soc Nephrol 6 2011 1903 1911
62. C. Nussbaum, A. Klinke, M. Adam, S. Baldus, and M. Sperandio Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease Antioxid Redox Signal 18 2013 692 713
63. R.K. Schindhelm, L.P. van der Zwan, T. Teerlink, and P.G. Scheffer Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem 55 2009 1462 1470
64. M. Karakas, and W. Koenig Myeloperoxidase production by macrophage and risk of atherosclerosis Curr Atheroscler Rep 14 2012 277 283
65. M. Karakas, W. Koenig, and A. Zierer et al. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study J Intern Med 271 2012 43 50
66. D. Mika, and C. Guruvayoorappan Myeloperoxidase: the yin and yang in tumour progression J Exp Ther Oncol 9 2011 93 100
67. B. Shao, M.N. Oda, J.F. Oram, and J.W. Heinecke Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein Chem Res Toxicol 23 2010 447 454
68. J. Himmelfarb Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Semin Dial 17 2004 449 454
69. J. Himmelfarb Relevance of oxidative pathways in the pathophysiology of chronic kidney disease Cardiol Clin 23 2005 319 330
70. A. Lehners, S. Lange, G. Niemann, et al. Myeloperoxidase deficiency ameliorates progression of chronic kidney disease in mice Am J Physiol Renal Physiol 307 2014 F407 F417
71. S. Rovira-Llopis, M. Rocha, R. Falcon, et al. Is myeloperoxidase a key component in the ROS-induced vascular damage related to nephropathy in type 2 diabetes? Antioxid Redox Signal 19 2013 1452 1458
72. A. Upadhyay, M.G. Larson, C.Y. Guo, et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort Nephrol Dial Transplant 26 2011 920 926
73. S. Sela, R. Shurtz-Swirski, M. Cohen-Mazor, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease J Am Soc Nephrol 16 2005 2431 2438
74. A. Madhusudhana Rao, U. Anand, and C.V. Anand Myeloperoxidase in chronic kidney disease Indian J Clin Biochem 26 2011 28 31
75. C. Capeillere-Blandin, V. Gausson, A.T. Nguyen, B. Descamps-Latscha, T. Drueke, and V. Witko-Sarsat Respective role of uraemic toxins and myeloperoxidase in the uraemic state Nephrol Dial Transplant 21 2006 1555 1563
76. A.Y. Wang, C.W. Lam, I.H. Chan, M. Wang, S.F. Lui, and J.E. Sanderson Prognostic value of plasma myeloperoxidase in ESRD patients Am J Kidney Dis 56 2010 937 946
77. N. Katakami, S. Kume, and H. Kaneto et al. Association of myeloperoxidase G-463A gene polymorphism with diabetic nephropathy in Japanese type 2 diabetic subjects Endocr J 60 2013 457 471
78. S.H. Ganji, V.S. Kamanna, and M.L. Kashyap Niacin decreases leukocyte myeloperoxidase: mechanistic role of redox agents and Src/p38MAP kinase Atherosclerosis 235 2014 554 561
79. M. Tepel, M. van der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, and W. Zidek Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine N Engl J Med 343 2000 180 184
80. ACT Investigators Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT) Circulation 124 2011 1250 1259
81. M. Boaz, S. Smetana, T. Weinstein, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial Lancet 356 2000 1213 1218
82. K. Endo, A. Saiki, T. Yamaguchi, et al. Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study J Atheroscler Thromb 20 2013 494 502
83. P.E. Pergola, P. Raskin, R.D. Toto, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes N Engl J Med 365 2011 327 336
84. M.P. Chin, S.A. Reisman, G.L. Bakris, et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl Am J Nephrol 39 2014 499 508
85. D. de Zeeuw, T. Akizawa, P. Audhya, et al; BEACON Trial Investigators Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease N Engl J Med 369 2013 2492 2503
86. S. Hamoud, M. Kaplan, E. Meilin, et al. Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol Am J Med Sci 345 2013 195 199
87. S.H. Ganji, S. Qin, L. Zhang, V.S. Kamanna, and M.L. Kashyap Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells Atherosclerosis 202 2009 68 75
88. P.R. Aveles, C.R. Criminacio, and S. Goncalves et al. Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation Nephron Clin Pract 116 2010 c294 c299
89. L.D. Bash, T.P. Erlinger, J. Coresh, J. Marsh-Manzi, A.R. Folsom, and B.C. Astor Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study Am J Kidney Dis 53 2009 596 605
90. D. Bolignano, A. Lacquaniti, G. Coppolino, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease Clin J Am Soc Nephrol 4 2009 337 344
91. L. Fried, C. Solomon, M. Shlipak, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals J Am Soc Nephrol 15 2004 3184 3191
92. Y.C. Tsai, C.C. Hung, M.C. Kuo, et al. Association of hsCRP, white blood cell count and ferritin with renal outcome in chronic kidney disease patients PLoS One 7 2012 e52775
93. M. Tonelli, C. Isles, T. Craven, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease Circulation 112 2005 171 178
94. K. Sharain, D. Hoppensteadt, V. Bansal, A. Singh, and J. Fareed Progressive increase of inflammatory biomarkers in chronic kidney disease and end-stage renal disease Clin Appl Thromb Hemost 19 2013 303 308
95. T.W. Hsu, K.L. Kuo, S.C. Hung, P.H. Huang, J.W. Chen, and D.C. Tarng Progression of kidney disease in non-diabetic patients with coronary artery disease: predictive role of circulating matrix metalloproteinase-2, -3, and -9 PLoS One 8 2013 e70132
96. S.T. Haller, P.A. Kalra, J.P. Ritchie, et al. Effect of CD40 and sCD40L on renal function and survival in patients with renal artery stenosis Hypertension 61 2013 894 900
97. R.W. Walters, A.K. Shukla, J.J. Kovacs, et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice J Clin Invest 119 2009 1312 1321
98. E. Holzhauser, C. Albrecht, Q. Zhou, et al. Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities J Cardiovasc Pharmacol 57 2011 447 454
99. C.M. Chesney, M.B. Elam, J.A. Herd, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT) Am Heart J 140 2000 631 636
100. T.H. Lin, W.C. Voon, H.W. Yen, et al. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan Kaohsiung J Med Sci 22 2006 257 265
101. J.F. Ferguson, P.N. Patel, R.Y. Shah, et al. Race and gender variation in response to evoked inflammation J Transl Med 11 2013 63
102. J. Wi, J.Y. Kim, S. Park, et al. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg Atherosclerosis 213 2010 235 240
103. K. Lee, T.H. Ahn, W.C. Kang, S.H. Han, I.S. Choi, and E.K. Shin The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis Korean Circ J 41 2011 641 648
104. V. Raptis, S. Kapoulas, and D. Grekas Role of asymmetrical dimethylarginine in the progression of renal disease Nephrology (Carlton) 18 2013 11 21
105. M.I. Yilmaz, M. Saglam, K. Caglar, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine Am J Kidney Dis 47 2006 42 50
106. M.J. Landray, J.R. Emberson, L. Blackwell, et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study Am J Kidney Dis 56 2010 1082 1094
107. G. Krenning, P.Y. Dankers, J.W. Drouven, et al. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease Am J Physiol Renal Physiol 296 2009 F1314 F1322
108. F. Perticone, R. Maio, M. Perticone, et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients Circulation 122 2010 379 384
109. A.S. Astrup, L. Tarnow, L. Pietraszek, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate Diabetes Care 31 2008 1170 1176
110. M. Lajer, L. Tarnow, A. Jorsal, T. Teerlink, H.H. Parving, and P. Rossing Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy Diabetes Care 31 2008 747 752
111. E. Boes, D. Fliser, E. Ritz, et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study J Am Soc Nephrol 17 2006 528 536
112. A. Warnholtz, P. Wild, M.A. Ostad, et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study Atherosclerosis 204 2009 216 221
113. S. Westphal, K. Borucki, C. Luley, J. Martens-Lobenhoffer, and S.M. Bode-Boger Treatment with niacin lowers ADMA Atherosclerosis 184 2006 448 450
114. A.C. Alfrey Effect of dietary phosphate restriction on renal function and deterioration Am J Clin Nutr 47 1988 153 156
115. S. Schwarz, B.K. Trivedi, K. Kalantar-Zadeh, and C.P. Kovesdy Association of disorders in mineral metabolism with progression of chronic kidney disease Clin J Am Soc Nephrol 1 2006 825 831
116. N. Voormolen, M. Noordzij, D.C. Grootendorst, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients Nephrol Dial Transplant 22 2007 2909 2916
117. S.C. Chen, J.M. Chang, W.C. Liu, et al. Brachial-ankle pulse wave velocity and rate of renal function decline and mortality in chronic kidney disease Clin J Am Soc Nephrol 6 2011 724 732
118. A. Bellasi, M. Mandreoli, L. Baldrati, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction Clin J Am Soc Nephrol 6 2011 883 891
119. L. De Nicola, R. Minutolo, P. Chiodini, et al. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care Kidney Int 82 2012 482 488
120. N. Noori, K. Kalantar-Zadeh, C.P. Kovesdy, R. Bross, D. Benner, and J.D. Kopple Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients Clin J Am Soc Nephrol 5 2010 683 692
121. C.D. Chue, N.C. Edwards, L.J. Davis, R.P. Steeds, J.N. Townend, and C.J. Ferro Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease Nephrol Dial Transplant 26 2011 2576 2582
122. C. Yuste, D. Barraca, I. Aragoncillo-Sauco, et al. Factors related with the progression of chronic kidney disease Nefrologia 33 2013 685 691
123. J.J. Sim, S.K. Bhandari, N. Smith, et al. Phosphorus and risk of renal failure in subjects with normal renal function Am J Med 126 2013 311 318
124. Y.S. Yap, W.C. Chi, C.H. Lin, Y.W. Wu, and Y.C. Liu Hyperphosphatemia is associated with overt proteinuria in non-diabetic patients with late-stage chronic kidney disease: a cross-sectional study Int Urol Nephrol 45 2013 163 172
125. B.R. Di Iorio, V. Bellizzi, A. Bellasi, et al. Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients Nephrol Dial Transplant 28 2013 632 640
126. C.P. Kovesdy, O. Kuchmak, J.L. Lu, and K. Kalantar-Zadeh Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD Am J Kidney Dis 56 2010 842 851
127. G.A. Block, D.C. Wheeler, M.S. Persky, et al. Effects of phosphate binders in moderate CKD J Am Soc Nephrol 23 2012 1407 1415
128. K. Shimoda, T. Akiba, T. Matsushima, T. Rai, K. Abe, and M. Hoshino [Niceritrol decreases serum phosphate levels in chronic hemodialysis patients] Nihon Jinzo Gakkai Shi 40 1998 1 7
129. N. Eto, Y. Miyata, H. Ohno, and T. Yamashita Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure Nephrol Dial Transplant 20 2005 1378 1384
130. K. Sampathkumar, M. Selvam, Y.S. Sooraj, S. Gowthaman, and R.N. Ajeshkumar Extended release nicotinic acid - a novel oral agent for phosphate control Int Urol Nephrol 38 2006 171 174
131. J.R. Guyton, A.E. Slee, T. Anderson, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1580 1584
132. D.H. Blankenhorn, S.A. Nessim, R.L. Johnson, M.E. Sanmarco, S.P. Azen, and L. Cashin-Hemphill Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 1987 3233 3240
133. M. Thoenes, A. Oguchi, S. Nagamia, et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome Int J Clin Pract 61 2007 1942 1948
134. A.J. Taylor, H.J. Lee, and L.E. Sullenberger The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2006 2243 2250
135. A.J. Taylor, T.C. Villines, E.J. Stanek, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
136. E. Bruckert, J. Labreuche, and P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
137. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression J Am Coll Cardiol 61 2013 440 446
138. V. Serebruany, A. Malinin, D. Aradi, W. Kuliczkowski, N.B. Norgard, and W.E. Boden The in vitro effects of niacin on platelet biomarkers in human volunteers Thromb Haemost 104 2010 311 317
139. No authors listed Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
140. L.A. Carlson, and G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
141. G. Brown, J.J. Albers, and L.D. Fisher et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
142. J.P. Kane, M.J. Malloy, T.A. Ports, N.R. Phillips, J.C. Diehl, and R.J. Havel Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens JAMA 264 1990 3007 3012
143. B.G. Brown, X.Q. Zhao, and A. Chait et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
144. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, and K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
145. E.J. Whitney, R.A. Krasuski, B.E. Personius, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events Ann Intern Med 142 2005 95 104
146. AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial Am Heart J 161 2011 538 543
147. F. Bonnet, M. Marre, J.M. Halimi, et al. DESIR Study Group Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study J Hypertens 24 2006 1157 1163
148. C. Kitiyakara, S. Yamwong, and S. Cheepudomwit et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort Kidney Int 71 2007 693 700
149. S.D. Navaneethan, J.D. Schold, and J.P. Kirwan et al. Metabolic syndrome, ESRD, and death in CKD Clin J Am Soc Nephrol 8 2013 945 952
150. M. Rahman, W. Yang, S. Akkina et al. for the CRIC Study Investigators Relation of serum lipids and lipoproteins with progression of CKD: the CRIC Study Clin J Am Soc Nephrol 9 2014 1190 1198
151. A. Rashidi, A. Ghanbarian, and F. Azizi Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney disease? Evidence based on data from a large cohort screening population Clin J Am Soc Nephrol 2 2007 976 983
152. F. Sun, Q. Tao, and S. Zhan Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort Nephrology (Carlton) 15 2010 84 92
153. A. Toda, Y. Ishizaka, M. Tani, and M. Yamakado Hyperuricemia is a significant risk factor for the onset of chronic kidney disease Nephron Clin Pract 126 2014 33 38
154. M. Tozawa, K. Iseki, C. Iseki, S. Oshiro, Y. Ikemiya, and S. Takishita Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria Kidney Int 62 2002 1743 1749
155. H. Watanabe, H. Obata, T. Watanabe, S. Sasaki, K. Nagai, and Y. Aizawa Metabolic syndrome and risk of development of chronic kidney disease: the Niigata preventive medicine study Diabetes Metab Res Rev 26 2010 26 32
156. D. Muller, H. Mehling, B. Otto, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients Clin J Am Soc Nephrol 2 2007 1249 1254
157. C.A. Restrepo Valencia, and J. Cruz [Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia] Nefrologia 28 2008 61 66
158. F. Ahmadi, F. Shamekhi, M. Lessan-Pezeshki, and M.R. Khatami Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients Saudi J Kidney Dis Transplant 23 2012 934 938
159. S. Hu, G.C. Shearer, M.W. Steffes, W.S. Harris, and A.G. Bostom Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia Am J Kidney Dis 57 2011 181 182
160. D. Maccubbin, D. Tipping, O. Kuznetsova, W.A. Hanlon, and A.G. Bostom Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial Clin J Am Soc Nephrol 5 2010 582 589
161. A.G. Bostom, A.A. Maclean, D. Maccubbin, D. Tipping, H. Giezek, and W.A. Hanlon Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes J Clin Lipidol 5 2011 281 287
162. J.H. Ix, P. Ganjoo, D. Tipping, A.M. Tershakovec, and A.G. Bostom Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients Am J Kidney Dis 57 2011 963 965
163. A. Baragetti, G.D. Norata, C. Sarcina, et al. High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease J Intern Med 274 2013 252 262
164. V. Chawla, T. Greene, G.J. Beck, et al. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease Clin J Am Soc Nephrol 5 2010 1582 1587
165. J.A. Cho, S.J. Lee, E.A. Reid, and S.H. Jee Metabolic syndrome component combinations and chronic kidney disease: the severance cohort study Maturitas 75 2013 74 80
166. L.G. Hunsicker, S. Adler, A. Caggiula, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study Kidney Int 51 1997 1908 1919
167. R. Klein, B.E. Klein, S.E. Moss, K.J. Cruickshanks, and P.C. Brazy The 10-year incidence of renal insufficiency in people with type 1 diabetes Diabetes Care 22 1999 743 751
168. Z.A. Massy, T. Nguyen Khoa, B. Lacour, B. Descamps-Latscha, N.K. Man, and P. Jungers Dyslipidaemia and the progression of renal disease in chronic renal failure patients Nephrol Dial Transplant 14 1999 2392 2397
169. P. Muntner, J. Coresh, J.C. Smith, J. Eckfeldt, and M.J. Klag Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study Kidney Int 58 2000 293 301
170. M. Ravid, D. Brosh, D. Ravid-Safran, Z. Levy, and R. Rachmani Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia Arch Intern Med 158 1998 998 1004
171. E.S. Schaeffner, T. Kurth, G.C. Curhan, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men J Am Soc Nephrol 14 2003 2084 2091
172. V.E. Torres, J.J. Grantham, A.B. Chapman, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 6 2011 640 647
173. T. Yoshida, T. Takei, S. Shirota, et al. Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population Intern Med 47 2008 1859 1864
174. G. Zoppini, C. Negri, V. Stoico, S. Casati, I. Pichiri, and E. Bonora Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus Metabolism 61 2012 22 29
175. R.P. Obermayr, C. Temml, M. Knechtelsdorfer, et al. Predictors of new-onset decline in kidney function in a general middle-european population Nephrol Dial Transplant 23 2008 1265 1273